Volta Labs Takes Center Stage at AGBT 2026 with Major Product Launches and Groundbreaking Partnerships

Volta Labs Stuns at AGBT 2026: Innovations in Genomic Sequencing

Volta Labs made a significant impact at the AGBT 2026, showcasing its innovative approach to genomic sequencing through several groundbreaking product launches and strategic partnerships. These advancements are set not only to redefine the operational landscape for genomic research but also to promote seamless automation in laboratory environments.

Strategic Collaborations and New Launches

At the heart of Volta Labs' announcements were new collaborations with Roche and Watchmaker Genomics™. These partnerships are intended to enhance the capabilities of their Callisto™ platform, shifting the sequencing workflow from a manual to an automated system, allowing labs to perform genomic sequences with the simple push of a button.

Roche's upcoming AXELIOS 1 has been integrated with Callisto, which streamlines the sample preparation workflow crucial for high-throughput sequencing. This collaboration exemplifies Volta's commitment to delivering high-quality automated library preparation services, especially for next-generation sequencing (NGS).

As stated by Volta Labs CEO Udayan Umapathi, “We aim to make the sequencing experience intuitive, providing our clients with the tools they need to automate high-quality sample preparation from day one.”

Advancements in Oncology Research

A standout moment during the conference was when the Hartwig Medical Foundation presented its research on circulating tumor DNA (ctDNA). This ambitious project aims to improve patient monitoring and treatment selection in oncology. Utilizing the Callisto platform, the foundation demonstrated an entirely automated ctDNA workflow that showcased efficient tumor tracking without the manual labor typically associated with genetic studies.

As emphasized in Hartwig's presentation, automating workflows is crucial for scaling operations in oncology, especially in environments where high throughput is key. Their results highlighted how Callisto's unique mixing capabilities can reduce ligation times, consequently speeding up vital processes.

Continual Evolution in Genomic Sequencing

Another major product unveiled was the fully integrated Callisto™ kit for enzyme-based library preparation. This kit, which has been optimized in collaboration with Watchmaker Genomics, allows for PCR-free genomic sequencing while minimizing user intervention. It’s a monumental step forward in making high-quality genomic sequencing accessible to more laboratories without increasing the workload or workflow complexity.

The presentations from world-renowned institutions like UMC Utrecht lent credibility to Callisto's capabilities. After nearly a year of using the platform, UMC Utrecht showcased significant improvements in consistency, reproducibility, and operational efficiency, emphasizing the growing demand underscored by their successful deployment of Callisto within diagnostic settings.

Embracing an Application-based Genomic Future

Volta Labs also outlined its vision for an application-driven genomics future at AGBT, emphasizing the importance of validated workflows that can mitigate the need for costly and repetitive development in laboratories. By focusing on ready-to-use applications, Volta aims to streamline the deployment of genomic solutions in clinical settings significantly.

“Sequencing innovation should not lead each laboratory to reinvent the workflow,” stated Udayan Umapathi, reinforcing Volta Labs' commitment to pushing the industry toward a fully automated genomic environment. Their goal is to ensure that the act of sequencing may soon only require the push of a button.

Conclusion

With its pioneering efforts at AGBT 2026, Volta Labs is undeniably setting a new standard in the realm of genomic sequencing. Their innovative technology and strategic partnerships reflect a firm commitment to advancing the field of genomics by making high-quality, automated sample preparation solutions accessible to laboratories worldwide. As the industry shifts towards automation, Volta Labs is certainly one to watch.

For further inquiries, please contact:

Nicole Ellis Ovadia
Director of Strategic Marketing
[email protected]

Volta Labs is headquartered in Boston, Massachusetts.